Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G versus MYHIBBIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G versus MYHIBBIN.
FULVICIN P/G vs MYHIBBIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to microtubule-associated proteins, disrupting mitotic spindle formation and inhibiting fungal cell division.
Myhibbin is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), thereby blocking the de novo synthesis of guanosine nucleotides. This inhibits T- and B-lymphocyte proliferation and antibody production.
250 mg orally twice daily for tinea infections; 500 mg orally twice daily for onychomycosis. Administer with a fatty meal to enhance absorption.
MYHIBBIN is not a recognized FDA-approved drug. No standard dosing information is available.
None Documented
None Documented
Terminal elimination half-life: 9–24 hours (mean ~16 hours). Clinical context: prolonged half-life allows once-daily dosing; steady-state achieved within 2–3 days.
Terminal half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours)
Renal (largely unchanged, <1% as metabolites); biliary/fecal (minor). Approximately 36% of a dose is excreted in urine within 6 hours, and up to 50% within 72 hours.
Renal excretion as unchanged drug (70-80%), biliary/fecal (15-20%)
Category C
Category C
Antifungal
Antifungal